

DOCTOR CONSENT

“Acute Otitis Media in Children: An Indian
Pediatricians’ Perspective on its Diagnosis
and Management (OMICIP Study)”

MA/12/21

Version No.:01

Date: 31/08/2021

SPONSOR:

Cipla Ltd,
Regd. Office Cipla House, Peninsula Business Park,
Ganpatrao Kadam Marg, Lower Parel, Mumbai – 400 013, Maharashtra, India.

Confidentiality statement:

This document contains proprietary information of the sponsor. All the information in this document including unpublished data exclusively belongs to the sponsor and must be treated as confidential. The information in this doctor consent shall be used solely for the purpose of review by the appropriate ethics committee or healthcare professional and only for performing this survey. Any disclosure or use of such information that is not authorized in writing by sponsor is strictly prohibited.

Dear Doctor,

Acute otitis media (AOM) is second most common cause for doctor visit in children after upper respiratory tract and early antibiotics have good role in preventing complications. Early but judicious use of antibiotics is a priority, as antimicrobial resistance represents a serious threat to global public health and the adherence to guideline may reduce the treatment failures, which are usually related to antibiotic resistant strains.

Cipla has been ahead of the curve in delivering advanced patient care. Extending our commitment to doctors and patients, we strive for yet another initiative in understanding the practice patterns in understanding the prevalence and various options for diagnosis and management of AOM in children.

Cipla is delighted to undertake this initiative titled “Acute Otitis Media in Children: An Indian Pediatricians’ Perspective on its Diagnosis and Management (OMICIP Study)” and it is our pleasure to invite you to participate in this important study. You are requested to answer the MCQ-based questionnaire that follows. The results of this survey will be analyzed to aid in understanding the current trends in the management of AOM in children.

We are highly obliged to you for participating in this initiative.

Regards,

Cipla

To,
Cipla Ltd
Peninsula Business Park
Ganpatrao Kadam Marg
Lower Parel, Mumbai – 400013

Dear Sir/Madam,

I understand that the objective of OMICIP Study is to understand the latest practice trends of the Indian pediatricians in the diagnosis and management of acute otitis media (AOM) in children. I hereby agree to share my experience with Cipla Ltd (hereinafter “Cipla”) and that Cipla shall have the unfettered right to use it in perpetuity, in all forms of media, including, but not limited, to print, audio, video, website, internet and such other media that is in existence today for display, exhibition, broadcast, transmission, communication or any other media that may come into existence at a future date.

I understand that Cipla shall have all rights to edit, reproduce, adapt, create derivative works or translate any information, views and opinion expressed by me as it deems fit, for the above-mentioned purpose, without my approval. I agree that this is not intended for any promotion or advertisement of any pharmaceutical product.

I hereby confirm that I shall notify Cipla if I attain a position to influence the purchasing decisions of a government entity or healthcare-related institution owned or substantially controlled by a government or public body. Such purchasing decisions may relate, for instance, to tenders issued by health authorities or decisions of formulary committees of public hospitals. Where such notification to Cipla is not permitted by local laws, regulations, I shall notify the purchase decision-maker in the said government entity, institution or hospital of my relationship with Cipla before any purchasing decision is made.

I am aware of and shall at all times abide by all the applicable laws governing medical professionals. I expressly release Cipla, its employees, representatives, agents etc., from

and against any and all claims arising out of the uses herein granted, including without limitation any claims for libel or violation of any right of publicity or privacy.

DATA COLLECTION:

Fill the e-questionnaire form provided to you. The e-questionnaire filled by you will be sent to a statistical agency for data entry and statistical analysis. The doctors (delegates) will gain access to the e-survey on a dedicated link post-registration of the conference. The doctor will be prompted digitally to read through the protocol, provide his consent and to complete the survey. The confidentiality of data would be maintained as the responses would be totally anonymous as they would be entered with each answer in the server. Proceeding to the next question (including concluding the survey) would be contingent upon answering its previous one, thus ensuring that all respondents answer all questions. The data captured on the Cipla server would only be shared with a statistical agency for analysis.

DATA SHARING CONSENT DECLARATION BY HEALTHCARE PROFESSIONAL/ INVESTIGATOR:

Kindly sign below after agreeing on each of the statement.

- ✓ I confirm that I have read and understood the survey protocol.
- ✓ I agree not to restrict the use of any data or results that arise from this survey provided such a use is only for scientific purpose(s).
- ✓ I agree to share medical data for the above survey.

Name of the healthcare professional: _____

Signature: _____ Date: _____

(DD/MM/YYYY)